Search clinical trials for: High risk node negative

Total 38049 results

National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa
Spanish Breast Cancer Research Group
Sanofi

Completed

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Breast Neoplasms

Spain
Spanish Breast Cancer Research Group
Bristol-Myers Squibb

Completed

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Breast Cancer

Spain
Danish Gynecological Cancer Group
European Organisation for Research and Treatment of Cancer - EORTC; Belgian... and other collaborators

Active, not recruiting

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Endometrial Cancer

Denmark
NSABP Foundation Inc
Genentech, Inc.; US Oncology Research

Completed

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Breast Cancer

United States, Ireland
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

China
Karolinska University Hospital
German Breast Group; Austrian Breast & Colorectal Cancer Study Group; Swedish...

Unknown

Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients (PANTHER)

Breast Cancer

Sweden, Germany, Austria
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
Martin-Luther-Universität Halle-Wittenberg
German Breast Group

Unknown

6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients (NNBC3-Europe)

Breast Cancer

Germany
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Breast Cancer

Greece
Sanofi

Completed

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

Breast Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Breast Cancer | Triple Negative Breast Cancer

United States
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)

Neoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast Cancer

China
Mayo Clinic

Not yet recruiting

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
Fundacao Champalimaud

Not yet recruiting

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab (KEYPARTNER)

Triple Negative Breast Cancer | Early Breast Cancer

Portugal
Major Extremity Trauma Research Consortium

Not yet recruiting

Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures: A Multicenter Randomized Controlled Trial (iVAC)

Wound Heal | Wound Complication | Wound Dehiscence | Fracture of Tibia | Infected Wound
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection

Non Muscle Invasive Bladder Cancer

China
Haaglanden Medical Centre
Tata Memorial Centre

Not yet recruiting

Towards Optimal Treatment for High Risk Prostate Cancer (HYPOPRIME)

High Risk Prostate Carcinoma

Netherlands
The First Affiliated Hospital of Soochow University

Recruiting

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

B Acute Lymphoblastic Leukemia | High Risk Acute Lymphoblastic Leukemia | Ph-Negative ALL

China
G. d'Annunzio University

Not yet recruiting

Probiotics in Special Needs Patients at High Risk for Tooth Decay: a Randomized Controlled Trial.

Intellectual Disability | Caries,Dental | Tooth Decay

Italy
University of Michigan Rogel Cancer Center

Recruiting

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer

Breast Cancer

United States
Ruijin Hospital

Recruiting

Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer

Breast Cancer

China
Qilu Hospital of Shandong University

Recruiting

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Bladder Cancer

China
NEAT ID Foundation
PENTA Foundation; European Commission; VERDI Consortium

Recruiting

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV (MASH 1)

Monkeypox | HIV Coinfection

Spain, France, Poland, United Kingdom
Johns Hopkins University
Castle Biosciences Incorporated

Recruiting

Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

Cutaneous Squamous Cell Carcinoma of the Head and Neck

United States
AstraZeneca

Recruiting

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA (ERA)

Breast Cancer

Russian Federation
Regina Elena Cancer Institute
Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Weizmann Institute... and other collaborators

Recruiting

Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus

Liquid Biopsy | Squamous Cell Carcinoma of the Oropharynx | Lymph Node Metastasis | Carcinomas of Unknown Primary Site | High-risk Human Papillomavirus Infection | Occult Tumor of the Head and Neck Area

Italy
Fudan University

Recruiting

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer

China
Ohio State University
DexCom, Inc.; Agency for Healthcare Research and Quality (AHRQ)

Not yet recruiting

Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching

Pregnancy, High Risk | Pre-Gestational Diabetes | Pregnancy in Diabetic | Type2diabetes

United States
Washington University School of Medicine
Varian Medical Systems

Recruiting

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Prostate Cancer | Cancer of the Prostate

United States
European Institute of Oncology

Recruiting

Radio-guided Surgery With DROP-IN Beta Probe for 68Ga-PSMA, in High-risk Prostate Cancer Patients Eligible for Robotic-assisted Radical Prostatectomy.

Prostate Cancer | Positron Emission Tomography | PSMA

Italy
Dana-Farber Cancer Institute

Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Lung Cancer | Cirrhosis | Barrett Esophagus | Hematologic Malignancy | Non-Alcoholic Fatty Liver Disease | Cancer Risk | Vulvar Intraepithelial Neoplasia | Childhood Cancer Survivors | Lung; Node | Non Alcoholic Steatohepatitis | Osteochondroma | Cancer Predisposition Syndrome | Hereditary Cancer Prediction | Adult... and other conditions

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
Gangnam Severance Hospital
Seoul National University

Recruiting

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk (INTERSTELLAR)

Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive Tumor | Premenopausal Breast Cancer | Node-positive Breast Cancer

Korea, Republic of
University Health Network, Toronto

Recruiting

Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer (MOB-RT)

Prostate Cancer

Canada
Cairo University

Recruiting

Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer

Prostate Cancer

Egypt
New York Medical College

Recruiting

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL)

Hodgkin Lymphoma | Non-hodgkin Lymphoma

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

Breast Cancer | Chemotherapy Effect

China
Peking University People's Hospital
Hangzhou Newhorizon Health Technology Co., Ltd.; Hangzhou Mingze Medical Research... and other collaborators

Recruiting

Clinical Evaluation of Detection of High Risk HPV in Urine (Urine-hrHPV)

Cervical Cancer | Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Human Papillomavirus Infection | Human Papilloma Virus | Adenocarcinoma in Situ | High-Grade Squamous Intraepithelial Lesions | Cervical Intraepithelial Neoplasia Grade II | Cervical Intraepithelial Neoplasia, Grade III | Atypical... and other conditions

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Relationship Between Lymph Node Dissection and Prognosis in High-risk NMIBC

Bladder Cancer

China
Norwegian University of Science and Technology
University Hospital of North Norway; Haukeland University Hospital; St. Olavs...

Recruiting

Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients

Prostatic Neoplasms | Neoplasm Metastasis

Norway
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Recruiting

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Triple-negative Breast Cancer | Carcinoma Breast | Invasive Ductal Carcinoma, Breast

China
University Hospital, Brest

Recruiting

Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ). (PREOP-PSMA)

Prostate Cancer

France
Criterium, Inc.

Recruiting

DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer (DARE)

Breast Cancer

United States
West German Study Group
Eli Lilly and Company; Genomic Health®, Inc.

Recruiting

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC (ADAPTlate)

Breast Cancer Female

Germany
Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Intrahepatic Cholangiocarcinoma Recurrent
McMaster University

Recruiting

Negative Pressure Incisional Wound Therapy for High-risk Ventral Hernia Repair (N-PITH)

Ventral Hernia

Canada
Israeli Medical Association

Recruiting

Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

High-Risk Cancer | Philadelphia-Negative ALL

Israel
University of Southern California
National Cancer Institute (NCI)

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)

Cancer | Metastatic | Breast | Triple Negative | Disseminated Tumor Cell

United States

Search clinical trials for: High risk node negative

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations